Roche promotes point-of-care head Schinecker to diagnostics CEO

Schinecker’s centralized and point-of-care unit showed 8% growth in 2018, driven mainly by expansions in its serum immunodiagnostics and clinical chemistry businesses. (Image: Roche)

Roche has promoted from within to find the new head of its diagnostics business.

Thomas Schinecker, global business head of the division’s burgeoning centralized and point-of-care solutions arm, will become CEO of Roche Diagnostics starting Aug. 1.

He’ll be taking over from Michael Heuer, who plans to retire at the end of next month after holding the post on an interim basis since last September, when former CEO Roland Diggelmann stepped down from the company.  


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

"Michael Heuer joined Roche following the acquisition of Boehringer Mannheim in 1998 and, after a long and distinguished career, has played a key role in making our company the world's leading provider of diagnostic solutions," Roche CEO Severin Schwan said in a statement.  

RELATED: Roche Diagnostics head Roland Diggelmann to step down

Schwan, a veteran of the diagnostics division himself, also cited Schinecker’s international experience. After beginning as a trainee in 2003, Schinecker has held management positions in marketing, sales and product development in Singapore, Austria, Sweden and the U.S., as well as general manager of Roche Diagnostics Germany. Going forward he will also serve as a member of the corporate executive committee.

Heuer, meanwhile, had joined Boehringer Mannheim in 1983, and following the acquisition held several roles before being named head of Roche’s Near Patient Testing business. He also served as head of diagnostics for Europe, the Middle East, Africa and Latin America.

RELATED: The top 10 medtech companies of 2024 | Roche

Roche’s diagnostics division accounted for over 22% of the Swiss group’s total international sales in 2018, bringing in $12.98 billion U.S. compared to the pharmaceutical side’s $44.29 billion.

And for the past two years, Schinecker’s centralized and point-of-care unit has been the largest contributor—it showed 8% growth in 2018, driven mainly by expansions in its serum immunodiagnostics and clinical chemistry businesses, and moves into the Asia-Pacific region.

Additionally, the company’s molecular and tissue diagnostics units also saw sales growth last year—of 5% and 10%, respectively—including in blood tests and screenings as well as in its slide staining portfolio and digital pathology work.

RELATED: Roche, GE launch integrated tumor diagnosis dashboard

Roche also announced further changes to its board of directors and corporate leadership: Peter Voser, a member since 2011, will step down at the end of this month after being named interim CEO of the Swiss engineering firm ABB this past April.

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.